Group 1 - The stock price of Jinkai Biotechnology closed at 39.04 yuan on August 13, 2025, reflecting an increase of 1.51% from the previous trading day [1] - The trading volume on that day was 55,624 hands, with a total transaction amount of 216 million yuan [1] - Jinkai Biotechnology focuses on the small molecule CDMO sector, with its main business encompassing the research, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients [1] Group 2 - The company emphasizes technological innovation as its core driving force and continues to deepen its engagement in the small molecule CDMO field [1] - In response to investor inquiries, the company stated it would carefully evaluate and advance measures that enhance long-term value, considering its development strategy, industry trends, and actual operating conditions [1] - On August 13, the net inflow of main funds was 9.1001 million yuan, accounting for 0.41% of the circulating market value, while the cumulative net outflow over the past five trading days was 42.4359 million yuan [1]

证券日报网讯 金凯生科（301509）8月13日在互动平台回答投资者提问时表示，公司始终专注于主营业 务发展，坚持以技术创新为核心驱动力，在小分子CDMO领域持续深耕，不断优化资源配置以提升核心 竞争力。公司会结合自身发展战略、行业趋势及实际经营情况，审慎评估并推进有利于提升公司长期价 值的举措。如有相关事项且达到信息披露标准，公司会及时履行信息披露义务，相关信息请以公司在指 定信息披露媒体发布的公告为准。 ...

每经AI快讯，8月12日，CRO指数盘中显著回调，现跌2.21%。成分股普遍走弱，成都先导跌4.14%、金 凯生科跌3.84%、阳光诺和跌3.82%、益诺思跌3.31%、奥浦迈跌2.86%领跌。 （文章来源：每日经济新闻） ...

重要的消息有哪些 1.《中华人民共和国增值税法实施条例（征求意见稿）》公开征求意见 财政部会同税务总局在认真研究并广泛听取意见建议基础上，研究形成了《中华人民共和国增值税法实 施条例（征求意见稿）》，现向社会公开征求意见。对增值税法规定的纳税人、征税范围等税制要素进 行细化和明确。一是明确应税交易中货物、服务、无形资产、不动产的定义范围（第二条）。二是对纳 税人中的单位和个人、一般纳税人和小规模纳税人进行解释（第三条、第六条、第七条）。三是明确服 务、无形资产在境内消费的情形（第四条）。四是明确增值税专用发票应分别注明销售额和增值税税额 （第五条）。 中汽协发布显示，7月，汽车出口57.5万辆，环比下降2.8%，同比增长22.6%。1—7月，汽车出口368万 辆，同比增长12.8%。1—7月新能源汽车产销累计完成823.2万辆和822万辆，同比分别增长39.2%和 38.5%。 2.中央结算公司：即日起不再要求境外央行类机构提供协议签署承诺书 中央国债登记结算有限责任公司发布关于简化境外央行类机构开户材料的通知，为落实中国人民银行相 关要求，进一步简化境外央行类机构入市投资流程，中央国债登记结算有限责任公司（ ...

Core Viewpoint - The company Jin Kai Sheng Ke (301509) is currently focused on small molecule CDMO services in the life sciences sector and does not engage in the PEEK materials field [1] Group 1 - The company is concentrating its efforts on the life sciences domain [1] - The existing products and services of the company do not involve PEEK materials [1]

Group 1 - The core viewpoint of the news is that Taihu Snow has been awarded the "ESG Corporate Governance Pioneer Award" for its outstanding practices in governance, highlighting its commitment to integrating economic efficiency with social responsibility [1] - The award is established by Securities Star in collaboration with professional institutions like Miaoying Technology, aiming to recognize companies that excel in governance practices such as compliance management and risk prevention [1] - Taihu Snow views governance as a cornerstone for steady progress, continuously refining its governance mechanisms and adhering to business ethics to lay a solid foundation for long-term development [3] Group 2 - In 2024, the company will establish an Environmental, Social, and Governance (ESG) Committee within its board to oversee sustainable development matters, responding better to the expectations of investors, customers, and other stakeholders [3] - Taihu Snow is optimizing its risk management mechanisms by considering market risks and uncertainties, enhancing its risk identification, evaluation, warning, and control processes to improve risk prediction and handling capabilities [4] - By the end of 2024, the company will have developed specific procedures for risk management and quality risk identification to strictly control potential risks and enhance the effectiveness of risk prevention [4]

Core Viewpoint - The company, Jinkai Life Science Technology Co., Ltd., specializes in providing custom research and development services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business of the company includes providing small molecule drug intermediates and custom R&D production services for new drug development projects from well-known global pharmaceutical companies [2][8]. - The company's revenue composition consists of 69.58% from fluorinated CDMO business, 29.10% from non-fluorinated CDMO business, 0.82% from trade and others, and 0.51% from technical services [8]. - As of July 31, the number of shareholders increased by 4.09% to 14,400, with an average of 3,939 circulating shares per person, a decrease of 3.93% [8]. Group 2: Financial Performance - For the first quarter of 2025, the company achieved a revenue of 176 million yuan, representing a year-on-year growth of 41.83%, and a net profit attributable to shareholders of 47.42 million yuan, up 183.24% year-on-year [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Group 3: Market Position and Trends - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 61.18% of total revenue [4]. - The stock price has shown a slight increase of 0.25% with a trading volume of 378 million yuan and a turnover rate of 16.14%, leading to a total market capitalization of 4.914 billion yuan [1].

证券之星消息，8月4日医疗服务板块较上一交易日下跌0.26%，昭衍新药领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 688265 | 南模生物 | 43.73 | 20.01% | | 4.08万 | 1.66亿 | | 688621 | 阳光诺和 | 66.54 | 14.84% | | 12.60万 | 8.15亿 | | 301201 | 诚达药业 | 28.10 | 4.04% | | 10.58万 | 2.93亿 | | 688222 | 成都先导 | 24.74 | 3.82% | | 33.55万 | 7.91亿 | | 002172 | 澳洋健康 | 4.25 | 3.41% | | 70.07万 | 2.93亿 | | 688046 | 药康生物 | 16.41 | 3.01% | | 4.55万 | 7293.23万 | | ...

Group 1 - The stock price of Jinkai Biotechnology is reported at 39.28 yuan as of July 30, 2025, reflecting a decline of 1.73% from the previous trading day [1] - The trading volume on the same day reached 263 million yuan, with a turnover rate of 11.73% [1] - Jinkai Biotechnology's main business includes bioproducts, weight loss drugs, and CRO services, and the company is part of the Liaoning sector with specialized and innovative qualifications [1] Group 2 - Shareholder Qilu Investment has reduced its holdings by a total of 4,477,700 shares between December 18, 2024, and July 28, 2025, accounting for 3.72% of the total share capital, bringing its ownership down to 4.99996% [1] - On July 30, 2025, the net outflow of main funds was 27.78 million yuan [1]

格隆汇7月29日丨金凯生科(301509.SZ)公布，公司于近日收到启鹭投资送达的《告知函》及《简式权益 变动报告书》，获悉启鹭投资通过集中竞价方式和大宗交易方式累计减持公司股份447.7720万股，减持 数量占总股本比例3.72%，持股数量降至602.2280万股，占公司总股本比例4.99996%，不再是公司持股 5%以上的股东。 ...